Clinical Research Directory
Browse clinical research sites, groups, and studies.
Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
Sponsor: First Affiliated Hospital of Guangxi Medical University
Summary
The benefit of intravenous tenecteplase in very old patients with acute ischemic stroke (AIS) remain uncertain. This real-world study aims to evaluate the effectiveness and safety of intravenous tenecteplase in AIS patients aged 80 years or older within 4.5 hours of symptom onset.
Official title: A Multicenter, Prospective, Observational, Real-World Registry Study of Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
Key Details
Gender
All
Age Range
80 Years - Any
Study Type
OBSERVATIONAL
Enrollment
392
Start Date
2026-04
Completion Date
2027-12
Last Updated
2026-03-17
Healthy Volunteers
No
Conditions
Interventions
Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
Tenecteplase is administered as a single intravenous bolus at a dose of 0.25 mg/kg, with a maximum of 25 mg.
Standard medical care
Standard medical treatment should adhere to clinical guidelines and usual care at site, including antiplatelet therapy, anticoagulant therapy, lipid-lowering therapy, antihypertensive drugs, etc., as determined by the local investigators.
Locations (1)
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China